Tag Archive for Q4 earnings

Betterware de México (BeFra) Reports Fourth Quarter 2025 Results

Guadalajara, Mexico – Betterware de México, S.A.P.I. de C.V. (NYSE:BWMX) (“BeFra” or the “Company”), announced today its consolidated financial results for the fourth quarter 2025.
The figures presented in this report are expressed in nominal Mexican Pesos (Ps.) unless otherwise noted, presented and approved by the Board of Directors, prepared in accordance with IFRS, and may include minor differences due to rounding.
Message from the President and CEO
Andrés Campos Chevallier, President and CEO of BeFra Group, shared:

“As we close the fourth quarter and full year 2025, we reflect on a year not marked by robust growth, but that highlighted the resilience of our business model, despite a year marked by macroeconomic volatility, socio-political uncertainty, and softer consumption trends across our core markets.
“Although net sales increased only slightly for both the quarter and full year, the performance of our business units continued to recover after a difficult 1Q25. JF Mexico continues to grow, BW Mexico progressively recovered from a weak start to the year, JF US delivered its first “back to growth” quarter, and BW Latam continues to deliver strong QoQ growth, validating the portability of our brand to new Latam markets.
“Profitability also recovered throughout the year, underpinned by disciplined expense management and despite extraordinary FX-related impacts to our

Read more...

Zinzino Preliminary Sales Report 2025

Zinzino group revenue increased 46% in Q4 and total revenue for the full year 2025 increased 51%, compared with the previous year.
The revenue in December for Zinzino‘s sales markets increased by 35% and amounted to SEK 334.4 (246.9) million. Faun Pharma’s external sales decreased and amounted to SEK 2.9 (5.8) million. Overall, the Group increased revenues by 33% to SEK 337.3 (252.7) million compared with the previous year.
Revenue in Zinzino’s sales markets increased by 50% in the fourth quarter of 2025 compared with the same period last year and amounted to SEK 1,032.3 (690.3) million. Total revenues in the Group increased by 46% in the fourth quarter and amounted to SEK 1,042.4 (713.5) million.
Accumulated revenue for January – December 2025 increased by 51% to SEK 3,344.5 (2,207.8) million.
Revenues were distributed as follows:

Regions, mSEK
25-Dec
24-Dec
Change
Q4 2025
Q4 2024
Change
YTD 2025
YTD 2024
Change

The Nordics
31.4
29.6
6%
98.4
88.0
12%
332.5
302.0
10%

Central Europe
102.9
78.1
32%
337.9
202.3
67%
995.4
596.7
67%

East Europe
36.3
34.5
5%
122.0
120.6
1%
398.0
400.4
-1%

South & West Europe
53.7
49.7
8%
167.8
131.9
27%
565.8
396.4
43%

The Baltics
18.0
12.0
50%
48.3
38.2
26%
133.5
107.6
24%

North America
52.0
21.1
146%
163.8
66.3
147%
545.7
200.5
172%

Asia-Pacific
37.4
20.2
85%
86.2
37.1
132%
299.4
84.6
254%

Africa
2.7
1.7
59%
7.8
5.9
32%
23.8
16.8
42%

Zinzino
334.4
246.9
35%
1,032.3
690.3
50%
3,294.1
2,105.0
56%

Faun Pharma
2.9
5.8
-50%
10.1
23.2
-57%
50.4
102.8
-51%

Zinzino Group
337.3
252.7
33%
1,042.4
713.5
46%
3,344.5
2,207.8
51%

Countries in regions:

The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
Central Europe: Austria, Germany, Switzerland
East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey, Canary Islands
The Baltics: Estonia, Latvia, Lithuania
North America: Canada, USA, Mexico
Asia-Pacific: Australia, New Zealand, Hong

Read more...